HomeAMGN • NASDAQ
Amgen Inc
add
$280.35
1.03%
After Hours:(0.15%)-0.41
$279.94
Closed: Jun 25, 7:33:07 PM UTC-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 8.15B | 9.43% |
Operating expense | 3.20B | 0.47% |
Net income | 1.73B | 1,630.97% |
Net profit margin | 21.23 | 1,496.71% |
Earnings per share | 4.90 | 23.74% |
EBITDA | 3.52B | 19.29% |
Effective tax rate | 12.32% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 8.81B | -9.25% |
Total assets | 89.37B | -3.89% |
Total liabilities | 83.16B | -5.45% |
Total equity | 6.21B | — |
Shares outstanding | 537.71M | — |
Price to book | 24.05 | — |
Return on assets | 6.46% | — |
Return on capital | 8.98% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | 1.73B | 1,630.97% |
Cash from operations | 1.39B | 101.89% |
Cash from investing | -447.00M | -105.99% |
Cash from financing | -4.11B | -140.46% |
Net change in cash | -3.16B | -155.91% |
Free cash flow | 1.21B | -34.48% |
Previous close
$277.49
Day range
$273.13 - $280.54
Year range
$253.30 - $346.85
Market cap
150.75B USD
Avg Volume
2.96M
P/E ratio
25.59
Dividend yield
3.40%
Primary exchange
NASDAQ
About
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp Wikipedia
Founded
Apr 8, 1980
Headquarters
Website
Employees
28,000
